Keymed Biosciences Announces 2023 Annual Results and Business Updates
- Written by PR Newswire
- Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA and granted priority review.
- Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of the clinical trial are positive with co-primary endpoints...
Read more: Keymed Biosciences Announces 2023 Annual Results and Business Updates














